Project Grant R01CA308059
Award Date 7/17/26
Completion Date 6/30/31
Dollars Obligated $423K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Memphis, TN 38105, USA
Similar Awards
- Federal Grant Award Summary ST Jude Children's Research Hospital Inc. received a $647,502 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective July 1, 2026 through June 30, 2031. This five-year research initiative focuses on developing novel anti-cancer therapeutics by targeting DDX19A, an RNA helicase identified as a genomic dependency in Ewing sarcoma, an aggressive pediatric bone malignancy. The research addresses...
- Federal Grant Award Summary St. Jude Children's Research Hospital Inc. received a $767,328 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), effective August 1, 2025 through July 31, 2030. The award funds research to investigate targeting splicing vulnerabilities in neuroblastoma, a malignancy responsible for 15% of childhood cancer-related deaths. The research will evaluate the efficacy and mechanisms of indisulam, a molecular glue...
- Federal Project Grant Award Summary ST Jude Children's Research Hospital Inc. received a $388,500 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective July 1, 2026, with completion targeted for February 28, 2030. The award funds investigator-initiated basic research exploring the molecular interaction between acyl-CoA synthetase long-chain family member 1 (ACSL1) and MCL-1 (myeloid...
- Federal Project Grant Award Summary St. Jude Children's Research Hospital Inc. received a $768,713 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective August 1, 2025, through July 31, 2030. This award supports fundamental research to advance understanding of epigenetic mechanisms controlling neuroblastoma cell state plasticity and treatment resistance. The project specifically investigates the role of histone...
- Federal Project Grant Award Summary St. Jude Children's Research Hospital Inc. received a $143,814 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), effective September 1, 2026, through August 31, 2028. This award supports biomedical research training and workforce development focused on pediatric cancer research aligned with the National Cancer Program. The funded project, "Reprogramming Chemoresistant Cell States in...
- Federal Project Grant Award Summary ST Jude Children's Research Hospital Inc. received a $628,073 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective June 1, 2026, with completion targeted for May 31, 2031. The award supports fundamental research investigating the mechanistic dissection and non-cell autonomous targeting of tumor promotion in DICER1 cancer predisposition. The primary deliverable is mechanistic research...
- Federal Grant Award Summary ST Jude Children's Research Hospital Inc. received a $579,874 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) awarded August 20, 2025, with completion targeted for July 31, 2030. This award supports a K08 career development grant focused on advancing the investigator's transition to independent research leadership in pediatric oncology. The primary deliverable is the design, implementation, and...
- Federal Grant Award Summary ST Jude Children's Research Hospital Inc. received a $617,486 Project Grant from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393) effective March 13, 2026, with completion scheduled for February 28, 2031. The award supports mechanistic research investigating how chimeric transcription factors—specifically PAX3-FOXO1 and PAX7-FOXO1—suppress intrinsic innate immunity in alveolar rhabdomyosarcoma (ARMS), an aggressive childhood...
- Federal Grant Award Summary St. Jude Children's Research Hospital Inc. received a $475,681 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) awarded on June 12, 2026, with a completion date of May 31, 2028. The project, "Exploring CLK2 as a Novel Therapeutic Target in Rhabdomyosarcoma," delivers translational research aimed at developing a new therapeutic approach to treat high-risk rhabdomyosarcoma (RMS), the most common...
- Federal Project Grant Award Summary St. Jude Children's Research Hospital Inc. received a $3,032,826 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) effective September 1, 2025, with a completion date of August 31, 2030. This award supports the FUSONC Program Project, which investigates fusion oncoproteins (FOPs)—abnormal proteins arising from gene translocations that drive approximately 17% of all cancers and are particularly...